Updates on immunotherapy for colorectal cancer
作者： Aparna Kalyan , Sheetal Kircher , Hiral Shah , Mary Mulcahy , Al Benson
关键词:
摘要: Despite significant advances in standard of care therapies, the 5-year survival rate for metastatic colorectal cancer (CRC) remains around 12%. Immunotherapy has not provided stellar that been seen other malignancies. appears to play a pivotal role microsatellite unstable CRC tumors where response rates are profound. These results have led FDA approval pembrolizumab MSI-H tumors. Additional research into several new immune agents including IDO inhibitors, vaccine therapy and combinatorial being evaluated CRC. This review will provide an overview approaches currently investigated.
amegroups.com参考文章(78)
Aarif Ahsan, Susmita G. Ramanand, Ingrid L. Bergin, Lilli Zhao, Christopher E. Whitehead, Alnawaz Rehemtulla, Dipankar Ray, William B. Pratt, Theodore S. Lawrence, Mukesh K. Nyati, Efficacy of an EGFR-Specific Peptide against EGFR-Dependent Cancer Cell Lines and Tumor Xenografts Neoplasia. ,vol. 16, pp. 105- 114 ,(2014) , 10.1593/NEO.14182
Hatem H. Soliman, Erica Jackson, Tony Neuger, E. Claire Dees, R. Donald Harvey, Hyo Han, Roohi Ismail-Khan, Susan Minton, Nicholas N. Vahanian, Charles Link, Daniel M. Sullivan, Scott Antonia, A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors Oncotarget. ,vol. 5, pp. 8136- 8146 ,(2014) , 10.18632/ONCOTARGET.2357
Rachel Lubong Sabado, Marcia Meseck, Nina Bhardwaj, Dendritic Cell Vaccines Vaccine Design. ,vol. 1403, pp. 763- 777 ,(2016) , 10.1007/978-1-4939-3387-7_44
Joseph R. Maxwell, Andrew Weinberg, Rodney A. Prell, Anthony T. Vella, Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. Journal of Immunology. ,vol. 164, pp. 107- 112 ,(2000) , 10.4049/JIMMUNOL.164.1.107
David A. Kooby, John F. Carew, Marc W. Halterman, Jonathan E. Mack, Joseph R. Bertino, Leslie H. Blumgart, Howard J. Federoff, Yuman Fong, Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207) The FASEB Journal. ,vol. 13, pp. 1325- 1334 ,(1999) , 10.1096/FASEBJ.13.11.1325
Feriyl Bhaijee, Thomas Huebner, Ralph H. Hruban, Laura D. Wood, Nathan Cuka, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Shibin Zhou, Toby C. Cornish, Janis M. Taube, Robert A. Anders, James R. Eshleman, Bert Vogelstein, Luis A. Diaz, Dung T. Le, Jennifer N. Uram, Hao Wang, Bjarne R. Bartlett, Holly Kemberling, Aleksandra D. Eyring, Andrew D. Skora, Brandon S. Luber, Nilofer S. Azad, Dan Laheru, Barbara Biedrzycki, Ross C. Donehower, Atif Zaheer, George A. Fisher, Todd S. Crocenzi, James J. Lee, Steven M. Duffy, Richard M. Goldberg, Albert de la Chapelle, Minori Koshiji, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency The New England Journal of Medicine. ,vol. 372, pp. 2509- 2520 ,(2015) , 10.1056/NEJMOA1500596
Jonathan Pol, Norma Bloy, Aitziber Buqué, Alexander Eggermont, Isabelle Cremer, Catherine Sautès-Fridman, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, Trial Watch: Peptide-based Anticancer Vaccines OncoImmunology. ,vol. 4, ,(2015) , 10.4161/2162402X.2014.974411
Julie Rowe, Putao Cen, TroVax in colorectal cancer Human Vaccines & Immunotherapeutics. ,vol. 10, pp. 3196- 3200 ,(2014) , 10.4161/21645515.2014.973323
Catherine Uyttenhove, Luc Pilotte, Ivan Théate, Vincent Stroobant, Didier Colau, Nicolas Parmentier, Thierry Boon, Benoît J Van den Eynde, None, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nature Medicine. ,vol. 9, pp. 1269- 1274 ,(2003) , 10.1038/NM934
C UYLDEGROOT, J VERMORKEN, M HANNAJR, P VERBOOM, M GROOT, G BONSEL, C MEIJER, H PINEDO, Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits Vaccine. ,vol. 23, pp. 2379- 2387 ,(2005) , 10.1016/J.VACCINE.2005.01.015